NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Globus Medical Inc. GMED
16 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in GLOBUS MEDICAL, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.
Growth
USD 2.9B
Revenue, FY2025 · full 16-year series below
Revenue $B
Net income $B
FY2025 · Revenue 2.9 · Net income 0.5
Compound annual growth
+42.2%
+30.1%
+18.4%
+16.7%
+41.4%
+39.4%
+16.9%
+16.5%
+28.4%
+31.2%
+12.9%
+13.3%
+27.0%
+45.5%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +30.1% a year over five years — but profit grew faster: net income at +39.4%, earnings per share at +31.2%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
18 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 16.3% · Net 18.3%
ROE
FY2025 · ROE 12.3%
Each USD of equity produced 12 cents of profit this year.
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 2.9 | 2.5 | 1.6 | 1.0 | 1.0 | 0.8 | 0.8 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 |
| Operating income $B | 0.5 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EBITDA $B | 0.8 | 0.4 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| Income tax $B | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.5 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Free cash flow $B | 0.6 | 0.4 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EPS, diluted $ | 3.92 | 0.75 | 1.07 | 1.85 | 1.44 | 1.01 | 1.52 | 1.54 | 1.10 | 1.08 | 1.17 | 0.97 | 0.73 | 0.80 | 0.67 | 0.60 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 12.3 | 2.5 | 4.2 | 10.6 | 9.2 | 7.0 | 12.0 | 14.5 | 11.9 | 13.5 | 17.3 | 17.5 | 16.0 | 22.1 | 23.8 | 23.9 |
| Shares out B | · | · | · | · | · | · | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 | 0.07 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 76 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 17 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2010